D

Dynavax Technologies Corp
D

DVAX

12.865
USD
0.15
(1.14%)
Market Open
Volume
13,401
EPS
0
Div Yield
-
P/E
86
Market Cap
1,690,505,654
OverviewSignalsIdeasNews
Related Instruments
    A
    ALT
    -0.38500
    (-4.65%)
    7.89000 USD
    B
    BCRX
    -0.12000
    (-1.59%)
    7.45000 USD
    E
    EBS
    -0.01000
    (-0.12%)
    8.08000 USD
    GSK
    GSK
    0.085
    (0.25%)
    33.680 USD
    I
    INO
    -0.04500
    (-2.46%)
    1.78500 USD
    MRNA
    MRNA
    0.290
    (0.74%)
    39.650 USD
    N
    NVAX
    -0.16000
    (-1.83%)
    8.56000 USD
    S
    SVA
    0.000000
    (0.00%)
    0.000000 USD
    TAK
    TAK
    -0.030
    (-0.23%)
    13.070 USD
    V
    VSTM
    -0.15000
    (-3.57%)
    4.05000 USD
    More
News

Title: Dynavax Technologies Corp

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.